查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2087378

血漿蛋白治療市場：2026-2032年全球市場預測（依產品、適應症、給藥途徑、劑型、治療模式、血漿來源類型、治療階段、聯合治療、年齡層及最終使用者分類）

Plasma Protein Therapeutics Market by Product, Indication, Route Of Administration, Dosage Form, Treatment Pattern, Plasma Source Type, Line Of Therapy, Therapy Combination, Age Group, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，血漿蛋白療法市場將成長至 437.8 億美元，複合年成長率為 5.35%。

主要市場統計數據
基準年 2025 303.8億美元
預計年份：2026年 319.7億美元
預測年份 2032 437.8億美元
複合年成長率 (%) 5.35%

血漿蛋白療法是利用人類血漿或重組技術生產的重要生物製藥，旨在取代、調節或補充必需蛋白質。此類別包括免疫球蛋白、白蛋白、凝血因子、α-1蛋白酶抑制劑、C1酯酶抑制劑以及其他用於治療原發性免疫力缺乏、原發性慢性脫髓鞘多發性神經炎、血友病、遺傳性血小板減少性疾病、肝病、休克、燒傷和重症監護的特殊血漿衍生療法。

這個市場由一種獨特的商業模式所塑造。供應始於合格的血漿捐贈者，經過嚴格監管的血漿採集和分離，最終製成符合嚴格品質、病毒安全性、藥物安全監測和低溫運輸標準的維持生命的療法。由於許多適應症需要定期或終身治療，因此需求結構穩健，但供應擴張取決於供應中心的容量、監管部門的批准、分離率和國家血漿採集政策。

就搜尋引擎最佳化和市場定位而言，最重要的行業主題包括免疫球蛋白使用量的增加、持續血漿採集的限制、重組和長效療法的普及、區域自給自足策略以及血漿業務的數位化。這些因素正在重新定義血漿蛋白治療領域製造商、合約分餾商、專業批發商、醫療保健系統和投資者的競爭優勢。

血漿蛋白治療產業的變革性變化

血漿蛋白治療產業的格局正從以銷售主導的擴張轉向以韌性主導的成長。由於免疫球蛋白的需求持續高於許多其他血漿衍生產品類型，製造商正增加對捐血者招募、採血中心效率、分離能力和產量最佳化等方面的投資。來自美國食品藥物管理局(FDA) 和歐洲藥品管理局 (EMA) 等監管機構的要求，進一步提高了對檢驗的生產流程、捐血者可追溯性、病原體去除和健全的品管系統的需求。

人工智慧（AI）的累積影響

人工智慧 (AI) 透過改善捐血者操作、生產製造、臨床開發和上市後監測等環節的決策，正在為血漿蛋白療法的整個價值鏈創造累積價值。 AI 驅動的分析技術可輔助進行捐血者預約安排、捐血者留存率建模、庫存規劃和需求預測，幫助機構降低血液採集能力直接影響治療藥物供應的供應波動。

對關鍵區域的洞察

北美仍然是血漿蛋白療法的關鍵區域。這是因為美國是全球最大的血漿採集地，也是免疫球蛋白、白蛋白和抗凝血藥物的主要需求中心。該地區受益於成熟的保險報銷體系、廣泛的專科藥房網路、先進的免疫和出血性疾病診斷系統，以及美國食品藥物管理局（FDA）對生物製藥生產和血漿採集的完善監管。在加拿大，除了高度監管的醫療保健環境外，臨床需求量也很大，並且全國範圍內都在努力確保患者能夠獲得血漿衍生藥物。

主要群體分析

由於七國集團（G7）國家醫療保健支出高、診斷流程完善、藥物安全監測體係成熟，且能夠廣泛獲得專業生技藥品，因此它們構成了全球血漿蛋白療法需求的基礎。其中，美國、日本、德國、法國、英國、義大利和加拿大在免疫球蛋白療法、白蛋白使用、血友病治療和罕見疾病管理等領域，對臨床標準、保險報銷決策、品質預期和療法應用具有重要影響力。

主要國家的概況

美國憑藉其大規模的血漿採集網路、FDA監管的生技藥品體系、先進的專科藥房分銷系統以及免疫球蛋白療法的高使用率，成為血漿蛋白療法領域最具影響力的國家。加拿大透過其醫療保健系統參與該領域，該系統強調強勁的臨床需求、監管准入和穩定的供應。墨西哥和巴西是拉丁美洲的重要市場，它們對診斷、保險覆蓋、公共採購和進口的依賴影響著免疫球蛋白、白蛋白、凝血因子和其他血漿衍生療法的引入。

為行業領導者提供的實用建議

產業領導者應優先考慮透過擴大符合倫理的血漿採集範圍、提高捐血者留存率、實現血漿來源地多元化以及投資提高血漿分離率來增強供應韌性。血漿衍生療法極易受到採集中斷的影響，因此，在採集、生產、品質、監管事務和分銷等各個環節進行整合規劃至關重要。

調查方法

本執行摘要採用系統化的二手研究途徑編寫，重點關注檢驗的公開資訊資訊來源、監管文件、臨床指南和行業證據。主要資訊來源美國食品藥物管理局(FDA)、歐洲藥品管理局 (EMA)、世界衛生組織 (WHO)、各國衛生組織、同行評審的免疫學和血液學文獻、臨床實踐指南以及成熟的血漿產業資源。

結論

血漿蛋白療法在生物製藥領域仍然佔據著至關重要的地位，因為它們用於治療嚴重的、慢性的、甚至危及生命的罕見疾病，而持續治療對這些疾病至關重要。免疫球蛋白的需求、特定適應症的明確、診斷技術的進步、醫院對白蛋白的使用、血友病治療的進展以及先進生物製藥可及性的提高，都支撐著這一領域的發展。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 血漿蛋白治療市場：依產品分類

  • 白蛋白
    • 百分之五
    • 百分之二十五
  • 凝血因子
    • 因子九
    • 因子 VIII
    • 凝血酶原複合物濃縮物
  • 高免疫球蛋白
    • B型肝炎
    • 狂犬病
    • 破傷風
    • 水痘和帶狀皰疹
  • 免疫球蛋白
    • 靜脈注射免疫球蛋白
    • 皮下注射免疫球蛋白

第8章：血漿蛋白治療市場：依適應症分類

  • 心血管系統
  • 神經系統
  • 原發性免疫力缺乏
  • 次發性免疫力缺乏
  • 創傷

第9章：血漿蛋白治療市場：依給藥途徑分類

  • 肌肉內部
  • 靜脈
  • 口服
  • 皮下

第10章：血漿蛋白治療市場：依劑型分類

  • 液體
  • 凍乾粉

第11章：血漿蛋白治療市場：依治療模式分類

  • 急性
  • 劇集類型
  • 慢性的

第12章：血漿蛋白治療市場：依血漿來源類型分類

  • 原始血漿
  • 回收的血漿

第13章：血漿蛋白治療市場：依治療階段分類

  • 一線治療
  • 第二行
  • 從第三行開始

第14章 血漿蛋白療法市場：依療法組合分類

  • 單藥治療
  • 聯合治療

第15章：血漿蛋白治療市場：依年齡層別分類

  • 兒童
  • 成人
  • 老年人

第16章：血漿蛋白治療市場：依最終用戶分類

  • 診所
  • 醫院

第17章 血漿蛋白治療市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第18章：血漿蛋白治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第19章：血漿蛋白治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第20章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第21章 公司簡介

  • Abeona Therapeutics Inc.
  • ADMA Biologics, Inc.
  • Amgen Inc.
  • Baxter International Inc.
  • Bayer AG
  • Bharat Serums and Vaccines Limited
  • Bio Products Laboratory Limited
  • Biogen Inc.
  • BioMarin Pharmaceutical Inc.
  • Biotest AG
  • China Biologic Products Holdings, Inc.
  • CSL Limited
  • Emergent BioSolutions Inc.
  • F. Hoffmann-La Roche Ltd.
  • GC Biopharma Corp.
  • Grifols SA
  • Hualan Biological Engineering, Inc.
  • Intas Pharmaceuticals Limited
  • Kamada Ltd.
  • Kedrion SpA
  • LFB SA
  • Novo Nordisk A/S
  • Octapharma AG
  • Pfizer Inc.
  • Prothya Biosolutions BV
  • Sanofi SA
  • Sanquin Plasma Products BV
  • Shanghai RAAS Blood Products Co., Ltd.
  • Shenzhen Kangtai Biological Products Co., Ltd.
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-030EE4851670

The Plasma Protein Therapeutics Market is projected to grow by USD 43.78 billion at a CAGR of 5.35% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 30.38 billion
Estimated Year [2026] USD 31.97 billion
Forecast Year [2032] USD 43.78 billion
CAGR (%) 5.35%

Plasma protein therapeutics are essential biologic medicines manufactured from human plasma or by recombinant technologies to replace, modulate, or supplement critical proteins. The category includes immunoglobulins, albumin, coagulation factors, alpha-1 proteinase inhibitor, C1 esterase inhibitor, and other specialty plasma-derived therapies used across primary immunodeficiency, chronic inflammatory demyelinating polyneuropathy, immune thrombocytopenia, hemophilia, hereditary angioedema, liver disease, shock, burns, and critical care.

The market is shaped by a distinctive operating model: supply begins with qualified plasma donors, continues through highly regulated plasma collection and fractionation, and ends with life-sustaining therapies subject to stringent quality, viral safety, pharmacovigilance, and cold-chain standards. Demand is structurally resilient because many indications require recurring or lifelong treatment, while supply expansion depends on donor center capacity, regulatory approvals, fractionation yield, and national plasma collection policies.

For SEO and market positioning, the most important industry themes are rising immunoglobulin utilization, persistent plasma collection constraints, broader use of recombinant and long-acting therapies, regional self-sufficiency strategies, and digitalization of plasma operations. These factors are redefining competitive advantage for manufacturers, contract fractionators, specialty distributors, health systems, and investors in plasma protein therapeutics.

Transformative Shifts in the Plasma Protein Therapeutics Landscape

The plasma protein therapeutics landscape is undergoing a shift from volume-led expansion to resilience-led growth. Manufacturers are investing in donor recruitment, collection-center productivity, fractionation capacity, and yield optimization as immunoglobulin demand continues to outpace many other plasma-derived product categories. Regulatory expectations from agencies such as the U.S. FDA and the European Medicines Agency reinforce the need for validated manufacturing processes, donor traceability, pathogen reduction, and robust quality systems.

Clinical practice is also transforming. Subcutaneous immunoglobulin is increasingly used for eligible patients who need more flexible administration, while recombinant coagulation factors and non-factor therapies have changed treatment pathways in hemophilia. At the same time, albumin remains deeply linked to hospital care, liver disease management, and intensive care protocols, making demand sensitive to clinical guidelines, hospital formularies, and reimbursement policies.

The competitive landscape is consolidating around organizations that can integrate plasma collection, fractionation, clinical evidence generation, regulatory compliance, and specialty distribution. Supply security, geographic diversification, patient-centric delivery formats, and validated quality systems are now as important as product portfolios in determining long-term leadership.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is creating cumulative value across the plasma protein therapeutics value chain by improving decisions in donor operations, manufacturing, clinical development, and post-market surveillance. AI-enabled analytics can support donor appointment scheduling, donor retention modeling, inventory planning, and demand forecasting, helping organizations reduce supply volatility in a category where collection capacity directly influences therapy availability.

In manufacturing, machine learning can strengthen process monitoring, deviation detection, batch-release analytics, and predictive maintenance for fractionation facilities. These applications align with broader regulatory interest in data integrity, quality-by-design, computerized system validation, and continuous process verification, provided models are validated and governed under appropriate quality management systems.

AI also has relevance in clinical and safety functions. Natural language processing can accelerate pharmacovigilance signal detection, while real-world evidence analytics can help clarify treatment patterns, adherence, dosing variability, and outcomes for immunoglobulin, albumin, coagulation factors, and rare disease therapies. The cumulative impact is not replacement of established biologics expertise, but faster and more reliable execution across highly regulated workflows.

Key Regional Insights

North America remains a pivotal region for plasma protein therapeutics because the United States is the world's largest source of collected plasma and a major demand center for immunoglobulin, albumin, and coagulation therapies. The region benefits from mature reimbursement systems, extensive specialty pharmacy networks, advanced diagnosis of immune and bleeding disorders, and established FDA oversight for biologics manufacturing and plasma collection. Canada adds a highly regulated healthcare environment with strong clinical demand and national attention to secure access for plasma-derived medicinal products.

Europe is characterized by strong regulatory harmonization through the European Medicines Agency and national competent authorities, although plasma collection and self-sufficiency policies vary by country. The European Union's focus on supply security, safety standards, pharmacovigilance, and cross-border medicinal product regulation continues to influence investment in fractionation capacity and plasma-derived medicinal product access. The United Kingdom, Germany, France, Italy, and Spain remain important treatment environments for immunology, hematology, neurology, and critical care indications.

Asia-Pacific is one of the most important development regions as China, India, Japan, South Korea, and Australia expand diagnosis, hospital infrastructure, biologics access, and regulatory capabilities. Japan, South Korea, and Australia show mature quality oversight and established specialty care, while China and India are shaped by large patient populations, evolving reimbursement, and domestic plasma policy. Latin America, led by Brazil and Mexico, shows rising demand but remains affected by uneven reimbursement, import dependence, and access disparities. The Middle East, particularly government-funded systems in the Gulf, is focused on imported therapy access and health security, while Africa faces the greatest challenges from limited domestic fractionation capacity, constrained diagnostics, and cold-chain reliability. Across all regions, donor policy modernization, public health investment, and dependable logistics are decisive for plasma protein therapeutics access.

Key Group Insights

The G7 countries anchor global demand for plasma protein therapeutics because they combine high healthcare expenditure, established diagnostic pathways, mature pharmacovigilance systems, and broad access to specialty biologics. Within this group, the United States, Japan, Germany, France, the United Kingdom, Italy, and Canada influence clinical standards, reimbursement decisions, quality expectations, and treatment adoption across immunoglobulin therapy, albumin use, hemophilia care, and rare disease management.

The European Union is central to regulatory alignment, pharmacovigilance, plasma-derived medicinal product policy, and cross-border supply security, while NATO countries collectively represent a large group of high-income healthcare systems where emergency preparedness, resilient medical supply chains, and biologics availability are increasingly relevant. BRICS markets are gaining strategic importance as China, India, and Brazil expand biologics access and hospital infrastructure, while Russia and South Africa reflect more variable access dynamics due to local policy, funding, and procurement conditions.

ASEAN presents long-term development potential as Indonesia, Thailand, Vietnam, Malaysia, the Philippines, and Singapore improve specialty care, diagnostic capability, and hospital infrastructure. GCC markets, including Saudi Arabia, the United Arab Emirates, Qatar, Kuwait, Bahrain, and Oman, are shaped by government-funded healthcare, import reliance, national health security priorities, and growing interest in specialized biologics access. Together, these blocs reveal a plasma protein therapeutics environment increasingly defined by regional procurement strategy, regulatory convergence, supply resilience, and plasma self-sufficiency ambitions.

Key Country Insights

The United States is the most influential country in plasma protein therapeutics because of its large plasma collection network, FDA-regulated biologics framework, advanced specialty pharmacy distribution, and high utilization of immunoglobulin therapies. Canada participates through strong clinical demand, regulated access, and health-system focus on stable supply. Mexico and Brazil represent important Latin American markets where diagnosis, reimbursement coverage, public procurement, and import dependence influence adoption of immunoglobulin, albumin, coagulation factors, and other plasma-derived therapies.

In Europe, Germany, France, Italy, Spain, and the United Kingdom have established treatment pathways for primary immunodeficiency, neurology, hematology, critical care, and rare disease indications. Germany and France are notable for sophisticated hospital systems and structured reimbursement pathways, while Italy and Spain combine broad public healthcare access with tendering and regional purchasing dynamics. The United Kingdom's clinical access is shaped by national guidance, specialized commissioning, and post-Brexit regulatory considerations. Russia remains a distinct market due to localization priorities, procurement controls, and variable access conditions. Across these countries, national health technology assessment, tendering, pharmacovigilance, and hospital purchasing policies shape therapy availability.

China and India are high-potential countries supported by large patient populations, expanding healthcare capacity, and increasing attention to rare disease and immunology diagnosis, while access continues to depend on reimbursement evolution, domestic plasma policy, and supply reliability. Japan shows mature biologics access, rigorous regulatory oversight, and established care for immunology, neurology, and hematology indications. South Korea combines advanced hospital infrastructure with strong regulatory capacity and increasing specialty biologics use. Australia has a highly regulated blood and plasma policy environment, strong clinical governance, and stable demand for plasma-derived and recombinant alternatives. Country-level performance depends on diagnosis rates, donor systems, reimbursement coverage, domestic manufacturing or import access, and the ability to secure continuity of treatment.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize supply resilience by expanding ethical plasma collection, improving donor retention, diversifying sourcing geographies, and investing in fractionation yield. Because plasma-derived therapies are vulnerable to collection disruptions, integrated planning across collection, manufacturing, quality, regulatory affairs, and distribution is essential.

Organizations should also strengthen evidence generation. Real-world data, patient registries, health economic analyses, and outcomes research can support payer discussions, refine dosing practices, and demonstrate value in immunoglobulin, albumin, coagulation therapies, and rare disease indications. Collaboration with clinicians, patient organizations, blood establishments, and regulators can improve diagnosis, appropriate utilization, and treatment continuity.

Digital transformation should be deployed selectively and responsibly. AI-enabled forecasting, quality analytics, donor engagement, inventory planning, and pharmacovigilance can deliver measurable value when supported by validated data, cybersecurity controls, auditability, and regulatory-grade governance. Leaders that combine supply security, clinical credibility, manufacturing excellence, and operational intelligence will be best positioned for sustainable growth.

Research Methodology

This executive summary is developed using a structured secondary-research approach focused on verifiable public sources, regulatory references, clinical guidelines, and industry evidence. Key inputs include information from the U.S. FDA, European Medicines Agency, World Health Organization, national health agencies, peer-reviewed immunology and hematology literature, clinical practice guidance, and established plasma industry resources.

The methodology emphasizes triangulation across demand drivers, product categories, regional policy environments, manufacturing constraints, healthcare access indicators, regulatory requirements, and documented therapeutic uses. Insights are assessed for consistency with established biologics frameworks, plasma collection and fractionation standards, pharmacovigilance expectations, and observed industry dynamics in cold-chain distribution and specialty medicine access.

Qualitative interpretation is applied to identify strategic implications for manufacturers, investors, distributors, healthcare providers, and public health stakeholders. No unsupported market-size estimate, market share statement, or forecast is used where a verifiable figure is not provided, preserving reliability and executive decision relevance.

Conclusion

Plasma protein therapeutics remain a critical segment of biologic medicine because they address severe, chronic, rare, and often life-threatening conditions where treatment continuity matters. The category is supported by immunoglobulin demand, specialty indications, improved diagnosis, hospital use of albumin, advances in hemophilia care, and broader access to advanced biologics.

At the same time, development is constrained by plasma availability, complex manufacturing, stringent regulatory requirements, cold-chain demands, and reimbursement pressure. The organizations best positioned for durable performance will be those that improve supply resilience, invest in quality and data systems, generate robust clinical evidence, and adapt to regional self-sufficiency priorities.

Artificial intelligence, recombinant innovation, and more sophisticated regional strategies will accelerate the next phase of plasma protein therapeutics evolution. For industry leaders, the category offers durable clinical relevance, but only disciplined execution can convert medical need into reliable patient access and sustainable competitive advantage.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Plasma Protein Therapeutics Market, by Product

  • 7.1. Albumin
    • 7.1.1. Five Percent
    • 7.1.2. Twenty Five Percent
  • 7.2. Coagulation Factor
    • 7.2.1. Factor IX
    • 7.2.2. Factor VIII
    • 7.2.3. Prothrombin Complex Concentrate
  • 7.3. Hyperimmune Globulin
    • 7.3.1. Hepatitis B
    • 7.3.2. Rabies
    • 7.3.3. Tetanus
    • 7.3.4. Varicella Zoster
  • 7.4. Immunoglobulin
    • 7.4.1. Intravenous Immunoglobulin
    • 7.4.2. Subcutaneous Immunoglobulin

8. Plasma Protein Therapeutics Market, by Indication

  • 8.1. Cardiovascular
  • 8.2. Neurological
  • 8.3. Primary Immunodeficiency
  • 8.4. Secondary Immunodeficiency
  • 8.5. Trauma

9. Plasma Protein Therapeutics Market, by Route Of Administration

  • 9.1. Intramuscular
  • 9.2. Intravenous
  • 9.3. Oral
  • 9.4. Subcutaneous

10. Plasma Protein Therapeutics Market, by Dosage Form

  • 10.1. Liquid
  • 10.2. Lyophilized Powder

11. Plasma Protein Therapeutics Market, by Treatment Pattern

  • 11.1. Acute
  • 11.2. Episodic
  • 11.3. Chronic

12. Plasma Protein Therapeutics Market, by Plasma Source Type

  • 12.1. Source Plasma
  • 12.2. Recovered Plasma

13. Plasma Protein Therapeutics Market, by Line Of Therapy

  • 13.1. First Line
  • 13.2. Second Line
  • 13.3. Third Line And Beyond

14. Plasma Protein Therapeutics Market, by Therapy Combination

  • 14.1. Monotherapy
  • 14.2. Combination Therapy

15. Plasma Protein Therapeutics Market, by Age Group

  • 15.1. Pediatric
  • 15.2. Adult
  • 15.3. Geriatric

16. Plasma Protein Therapeutics Market, by End User

  • 16.1. Clinics
  • 16.2. Hospitals

17. Plasma Protein Therapeutics Market, by Region

  • 17.1. Asia-Pacific
  • 17.2. North America
  • 17.3. Latin America
  • 17.4. Europe
  • 17.5. Middle East
  • 17.6. Africa

18. Plasma Protein Therapeutics Market, by Group

  • 18.1. ASEAN
  • 18.2. GCC
  • 18.3. European Union
  • 18.4. BRICS
  • 18.5. G7
  • 18.6. NATO

19. Plasma Protein Therapeutics Market, by Country

  • 19.1. United States
  • 19.2. Canada
  • 19.3. Mexico
  • 19.4. Brazil
  • 19.5. United Kingdom
  • 19.6. Germany
  • 19.7. France
  • 19.8. Russia
  • 19.9. Italy
  • 19.10. Spain
  • 19.11. China
  • 19.12. India
  • 19.13. Japan
  • 19.14. Australia
  • 19.15. South Korea

20. Competitive Landscape

  • 20.1. Market Concentration Analysis, 2025
    • 20.1.1. Concentration Ratio (CR)
    • 20.1.2. Herfindahl Hirschman Index (HHI)
  • 20.2. Recent Developments & Impact Analysis, 2025
  • 20.3. Product Portfolio Analysis, 2025
  • 20.4. Benchmarking Analysis, 2025

21. Company Profiles

  • 21.1. Abeona Therapeutics Inc.
  • 21.2. ADMA Biologics, Inc.
  • 21.3. Amgen Inc.
  • 21.4. Baxter International Inc.
  • 21.5. Bayer AG
  • 21.6. Bharat Serums and Vaccines Limited
  • 21.7. Bio Products Laboratory Limited
  • 21.8. Biogen Inc.
  • 21.9. BioMarin Pharmaceutical Inc.
  • 21.10. Biotest AG
  • 21.11. China Biologic Products Holdings, Inc.
  • 21.12. CSL Limited
  • 21.13. Emergent BioSolutions Inc.
  • 21.14. F. Hoffmann-La Roche Ltd.
  • 21.15. GC Biopharma Corp.
  • 21.16. Grifols S.A.
  • 21.17. Hualan Biological Engineering, Inc.
  • 21.18. Intas Pharmaceuticals Limited
  • 21.19. Kamada Ltd.
  • 21.20. Kedrion S.p.A.
  • 21.21. LFB S.A.
  • 21.22. Novo Nordisk A/S
  • 21.23. Octapharma AG
  • 21.24. Pfizer Inc.
  • 21.25. Prothya Biosolutions B.V.
  • 21.26. Sanofi S.A.
  • 21.27. Sanquin Plasma Products B.V.
  • 21.28. Shanghai RAAS Blood Products Co., Ltd.
  • 21.29. Shenzhen Kangtai Biological Products Co., Ltd.
  • 21.30. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY TREATMENT PATTERN, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY TREATMENT PATTERN, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PLASMA SOURCE TYPE, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PLASMA SOURCE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY THERAPY COMBINATION, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY THERAPY COMBINATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 27. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 29. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 31. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 32. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 33. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ALBUMIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ALBUMIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ALBUMIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL FIVE PERCENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL FIVE PERCENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL FIVE PERCENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL TWENTY FIVE PERCENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL TWENTY FIVE PERCENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL TWENTY FIVE PERCENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL COAGULATION FACTOR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL COAGULATION FACTOR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL COAGULATION FACTOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL FACTOR IX MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL FACTOR IX MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL FACTOR IX MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL FACTOR VIII MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL FACTOR VIII MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL FACTOR VIII MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PROTHROMBIN COMPLEX CONCENTRATE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PROTHROMBIN COMPLEX CONCENTRATE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PROTHROMBIN COMPLEX CONCENTRATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL HYPERIMMUNE GLOBULIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL HYPERIMMUNE GLOBULIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL HYPERIMMUNE GLOBULIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL HEPATITIS B MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL HEPATITIS B MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL HEPATITIS B MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL RABIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL RABIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL RABIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL TETANUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL TETANUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL TETANUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL VARICELLA ZOSTER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL VARICELLA ZOSTER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL VARICELLA ZOSTER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL IMMUNOGLOBULIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL IMMUNOGLOBULIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CARDIOVASCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CARDIOVASCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CARDIOVASCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NEUROLOGICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NEUROLOGICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL NEUROLOGICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PRIMARY IMMUNODEFICIENCY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PRIMARY IMMUNODEFICIENCY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PRIMARY IMMUNODEFICIENCY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL SECONDARY IMMUNODEFICIENCY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL SECONDARY IMMUNODEFICIENCY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL SECONDARY IMMUNODEFICIENCY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL TRAUMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL TRAUMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL TRAUMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL LIQUID MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL LIQUID MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL LIQUID MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL LYOPHILIZED POWDER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL LYOPHILIZED POWDER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL LYOPHILIZED POWDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY TREATMENT PATTERN, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ACUTE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ACUTE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ACUTE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL EPISODIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL EPISODIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL EPISODIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CHRONIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CHRONIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CHRONIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PLASMA SOURCE TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL SOURCE PLASMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL SOURCE PLASMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL SOURCE PLASMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL RECOVERED PLASMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL RECOVERED PLASMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL RECOVERED PLASMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL FIRST LINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL FIRST LINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL FIRST LINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL SECOND LINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL SECOND LINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL SECOND LINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL THIRD LINE AND BEYOND MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL THIRD LINE AND BEYOND MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL THIRD LINE AND BEYOND MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY THERAPY COMBINATION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL MONOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL MONOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL MONOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL COMBINATION THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL COMBINATION THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL ADULT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL ADULT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY TREATMENT PATTERN, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PLASMA SOURCE TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY THERAPY COMBINATION, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY TREATMENT PATTERN, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PLASMA SOURCE TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY THERAPY COMBINATION, 2018-2032 (USD MILLION)
  • TABLE 164. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY TREATMENT PATTERN, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PLASMA SOURCE TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 178. LATIN AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY THERAPY COMBINATION, 2018-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 180. LATIN AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY TREATMENT PATTERN, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PLASMA SOURCE TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY THERAPY COMBINATION, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST PLASMA PROTEIN THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 202. MIDDLE EAST PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 204. MIDDLE EAST PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY TREATMENT PATTERN, 2018-2032 (USD MILLION)
  • TABLE 206. MIDDLE EAST PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PLASMA SOURCE TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 208. MIDDLE EAST PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY THERAPY COMBINATION, 2018-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 210. MIDDLE EAST PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 211. AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 212. AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 213. AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2032 (USD MILLION)
  • TABLE 214. AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2032 (USD MILLION)
  • TABLE 215. AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 216. AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 217. AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 218. AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 219. AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 220. AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY TREATMENT PATTERN, 2018-2032 (USD MILLION)
  • TABLE 221. AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PLASMA SOURCE TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 223. AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY THERAPY COMBINATION, 2018-2032 (USD MILLION)
  • TABLE 224. AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 225. AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 226. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 229. ASEAN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2032 (USD MILLION)
  • TABLE 230. ASEAN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2032 (USD MILLION)
  • TABLE 231. ASEAN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 232. ASEAN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 233. ASEAN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 234. ASEAN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 235. ASEAN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 236. ASEAN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY TREATMENT PATTERN, 2018-2032 (USD MILLION)
  • TABLE 237. ASEAN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PLASMA SOURCE TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. ASEAN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 239. ASEAN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY THERAPY COMBINATION, 2018-2032 (USD MILLION)
  • TABLE 240. ASEAN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 241. ASEAN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 242. GCC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 243. GCC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 244. GCC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2032 (USD MILLION)
  • TABLE 245. GCC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2032 (USD MILLION)
  • TABLE 246. GCC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 247. GCC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 248. GCC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 249. GCC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 250. GCC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 251. GCC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY TREATMENT PATTERN, 2018-2032 (USD MILLION)
  • TABLE 252. GCC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PLASMA SOURCE TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. GCC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 254. GCC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY THERAPY COMBINATION, 2018-2032 (USD MILLION)
  • TABLE 255. GCC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 256. GCC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION PLASMA PROTEIN THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPEAN UNION PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPEAN UNION PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPEAN UNION PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPEAN UNION PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPEAN UNION PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPEAN UNION PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPEAN UNION PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPEAN UNION PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY TREATMENT PATTERN, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPEAN UNION PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PLASMA SOURCE TYPE, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPEAN UNION PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY THERAPY COMBINATION, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPEAN UNION PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 271. EUROPEAN UNION PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 272. BRICS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 273. BRICS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 274. BRICS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2032 (USD MILLION)
  • TABLE 275. BRICS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2032 (USD MILLION)
  • TABLE 276. BRICS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 277. BRICS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 278. BRICS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 279. BRICS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 280. BRICS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 281. BRICS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY TREATMENT PATTERN, 2018-2032 (USD MILLION)
  • TABLE 282. BRICS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PLASMA SOURCE TYPE, 2018-2032 (USD MILLION)
  • TABLE 283. BRICS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 284. BRICS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY THERAPY COMBINATION, 2018-2032 (USD MILLION)
  • TABLE 285. BRICS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 286. BRICS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 287. G7 PLASMA PROTEIN THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 288. G7 PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 289. G7 PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2032 (USD MILLION)
  • TABLE 290. G7 PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2032 (USD MILLION)
  • TABLE 291. G7 PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 292. G7 PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 293. G7 PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 294. G7 PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 295. G7 PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 296. G7 PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY TREATMENT PATTERN, 2018-2032 (USD MILLION)
  • TABLE 297. G7 PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PLASMA SOURCE TYPE, 2018-2032 (USD MILLION)
  • TABLE 298. G7 PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 299. G7 PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY THERAPY COMBINATION, 2018-2032 (USD MILLION)
  • TABLE 300. G7 PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 301. G7 PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 302. NATO PLASMA PROTEIN THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 303. NATO PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 304. NATO PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2032 (USD MILLION)
  • TABLE 305. NATO PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2032 (USD MILLION)
  • TABLE 306. NATO PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 307. NATO PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 308. NATO PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 309. NATO PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 310. NATO PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 311. NATO PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY TREATMENT PATTERN, 2018-2032 (USD MILLION)
  • TABLE 312. NATO PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PLASMA SOURCE TYPE, 2018-2032 (USD MILLION)
  • TABLE 313. NATO PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 314. NATO PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY THERAPY COMBINATION, 2018-2032 (USD MILLION)
  • TABLE 315. NATO PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 316. NATO PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 317. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 318. UNITED STATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 319. UNITED STATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 320. UNITED STATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2032 (USD MILLION)
  • TABLE 321. UNITED STATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2032 (USD MILLION)
  • TABLE 322. UNITED STATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 323. UNITED STATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 324. UNITED STATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 325. UNITED STATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 326. UNITED STATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 327. UNITED STATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY TREATMENT PATTERN, 2018-2032 (USD MILLION)
  • TABLE 328. UNITED STATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PLASMA SOURCE TYPE, 2018-2032 (USD MILLION)
  • TABLE 329. UNITED STATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 330. UNITED STATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY THERAPY COMBINATION, 2018-2032 (USD MILLION)
  • TABLE 331. UNITED STATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 332. UNITED STATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 333. CANADA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 334. CANADA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 335. CANADA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2032 (USD MILLION)
  • TABLE 336. CANADA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2032 (USD MILLION)
  • TABLE 337. CANADA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 338. CANADA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 339. CANADA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 340. CANADA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 341. CANADA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 342. CANADA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY TREATMENT PATTERN, 2018-2032 (USD MILLION)
  • TABLE 343. CANADA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PLASMA SOURCE TYPE, 2018-2032 (USD MILLION)
  • TABLE 344. CANADA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 345. CANADA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY THERAPY COMBINATION, 2018-2032 (USD MILLION)
  • TABLE 346. CANADA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 347. CANADA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 348. MEXICO PLASMA PROTEIN THERAPEU